Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

513 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer.
Wagner AH, Devarakonda S, Skidmore ZL, Krysiak K, Ramu A, Trani L, Kunisaki J, Masood A, Waqar SN, Spies NC, Morgensztern D, Waligorski J, Ponce J, Fulton RS, Maggi LB Jr, Weber JD, Watson MA, O'Conor CJ, Ritter JH, Olsen RR, Cheng H, Mukhopadhyay A, Can I, Cessna MH, Oliver TG, Mardis ER, Wilson RK, Griffith M, Griffith OL, Govindan R. Wagner AH, et al. Among authors: masood a. Nat Commun. 2018 Sep 17;9(1):3787. doi: 10.1038/s41467-018-06162-9. Nat Commun. 2018. PMID: 30224629 Free PMC article.
Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC.
Morgensztern D, Du L, Waqar SN, Patel A, Samson P, Devarakonda S, Gao F, Robinson CG, Bradley J, Baggstrom M, Masood A, Govindan R, Puri V. Morgensztern D, et al. Among authors: masood a. J Thorac Oncol. 2016 Oct;11(10):1729-35. doi: 10.1016/j.jtho.2016.05.022. Epub 2016 Jun 8. J Thorac Oncol. 2016. PMID: 27287414 Free PMC article.
Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.
Devarakonda S, Rotolo F, Tsao MS, Lanc I, Brambilla E, Masood A, Olaussen KA, Fulton R, Sakashita S, McLeer-Florin A, Ding K, Le Teuff G, Shepherd FA, Pignon JP, Graziano SL, Kratzke R, Soria JC, Seymour L, Govindan R, Michiels S. Devarakonda S, et al. Among authors: masood a. J Clin Oncol. 2018 Oct 20;36(30):2995-3006. doi: 10.1200/JCO.2018.78.1963. Epub 2018 Aug 14. J Clin Oncol. 2018. PMID: 30106638 Free PMC article.
Genomic Profiling of Lung Adenocarcinoma in Never-Smokers.
Devarakonda S, Li Y, Martins Rodrigues F, Sankararaman S, Kadara H, Goparaju C, Lanc I, Pepin K, Waqar SN, Morgensztern D, Ward J, Masood A, Fulton R, Fulton L, Gillette MA, Satpathy S, Carr SA, Wistuba I, Pass H, Wilson RK, Ding L, Govindan R. Devarakonda S, et al. Among authors: masood a. J Clin Oncol. 2021 Nov 20;39(33):3747-3758. doi: 10.1200/JCO.21.01691. Epub 2021 Sep 30. J Clin Oncol. 2021. PMID: 34591593 Free PMC article.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib.
Masood A, Kancha RK, Subramanian J. Masood A, et al. Semin Oncol. 2019 Jun;46(3):271-283. doi: 10.1053/j.seminoncol.2019.08.004. Epub 2019 Sep 11. Semin Oncol. 2019. PMID: 31558282 Free article. Review.
Recent preclinical data indicate that second-generation ErbB family blockers, such as afatinib, have a broad activity profile across uncommon EGFR mutations. Emerging evidence indicates that the preclinical data for afatinib are reflected in the clinic. ...To see an abstra …
Recent preclinical data indicate that second-generation ErbB family blockers, such as afatinib, have a broad activity profile across …
513 results